Insight Molecular Diagnostics Inc. — Director's Dealing 2021

Oct 14, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2021-06-24

Reporting Person: Yu Li (VP Cntrllr/Prncpl Acctng Offcr)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-24	Option to Purchase Common Stock	$4.33	A	160000	Acquired	2031-05-18	Common Stock (160000)	Direct

Footnotes

F1: This option award was granted on May 18, 2021, but such award was subject to shareholder approval of an increase in the number of shares available for issuance under the Oncocyte 2018 Equity Incentive Plan. Such shareholder approval was received on June 24, 2021.

F2: 25% of the options will become exercisable after one year of continuous employment from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continued employment on the applicable vesting date.